Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus FOLFIRI as first-line treatment for advanced or metastatic gastric cancer
2004-004072-37Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Sant'Orsola-Malpighi University Hospital. Started Apr 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2004-004072-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004072-37.